Published: October 29, 2025 at 8:49 am
Allergy Therapeutics has strengthened its finances after raising £55 million from the exercise of 1.38 billion lender warrants, using the proceeds to fully repay its shareholder loan and clear all outstanding debt.
The West Sussex-based MedTech, which develops allergy vaccines and immunotherapy treatments, said the move leaves it with a stronger balance sheet and more room to grow as it prepares for key product milestones.
The company has also agreed a new £50m unsecured loan facility with long-term backers SkyGem Acquisition Limited and Southern Fox Investments Limited, providing financial flexibility until 2030.